ID

38593

Descrição

Study ID: 110951 Clinical Study ID: 110951 Study Title: A two-part, randomised, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of intravenously infused GSK1995057 in healthy subjects. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01476046 See https://clinicaltrials.gov/ct2/show/NCT01476046 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: N/A, Placebo Trade Name: N/A Study Indication: Respiratory Disorders This phase I trial primarily studies the safety and tolerability of ascending single intravenous doses of the selective TNFR1 antagonist GSK1995057 in healthy volunteers, and secondly explores the drug's pharmacodynamics, pharmacokinetics, concentration in lung epithelial lining fluid as well as its effect on immune system markers. The drug is hypothesized to be useful for Acute Lung Injury. The single-centre study consists of two parts A and B with seven cohorts/ten subcohorts in total. Part A includes ascending doses of the investigational product given to subjects negative or positive for pre-existing human anti-heavy chain variable domain (HAVH) antibodies (Cohorts 1 to 3 with Subcohorts 1a, 2a and 3a negative for HAVH and 1b, 2b, 3b positive for HAVH). Part B includes only subjects negative for HAVH, with ascending doses given to Cohorts 4 to 6. Cohort 7 receives the same dose as Cohort 6, but whereas the other Cohorts are single-blinded, Cohort 7 is open-label and additionally receives a bronchoalveolar lavage (BAL). The study consists of a Screening Visit (up to 56 days before Day 1, the day of the drug administration), Visits on Day -1, 1, 2, 3, 5, 7, 14, 28 and Follow-Up Visits on Day 57 and 85. This form contains information on serum or WBA samples collected for biomarker assessment. Scheduled time points of collection are: Day -1, additional 2nd sample on Day -1 only for BWA in Study Part A, Day 1 2 Hours Post Start of Infusion, Day 1 6 Hours Post Start of Infusion (in Study Part A only for Serum, in Study Part B for Serum and WBA), Day 2, Day 3 (in Study Part A only for Serum, in Study Part B for Serum and WBA), and Day 28 (Serum only in both Study Parts); additional unscheduled collection can also be recorded in this form.

Link

https://clinicaltrials.gov/ct2/show/NCT01476046

Palavras-chave

Versões (1)

1. 25.10.19 25.10.19 -

Titular dos direitos

GlaxoSmithKline

Transferido a

25. Oktober 2019

DOI

Para um pedido faça login.

Licença